Adherence to Intravitreal Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Drugs in Diabetic Macular Edema in an Egyptian Population: A Health Belief Model

References

• Keenan TD, Johnston RL, Donachie PH, Sparrow JM, Stratton IM, Scanlon P. United Kingdom national ophthalmology database study: diabetic retinopathy; report 1: prevalence of centre-involving diabetic macular oedema and other grades of maculopathy and retinopathy in hospital eye services. Eye (Lond). 2013;27(12):1397–404. doi:10.1038/eye.2013.196.
   PubMed Web of Science ®Google Scholar
• Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007 Jul-Aug;14(4):179–83. doi:10.1080/09286580701396720.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Causes of blindness and visual impairment. [ Accessed 2018 Oct 6]. http://www.who.int/blindness/causes/en/.
   Google Scholar
• Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, Chen S-J, Dekker JM, Fletcher A, Grauslund J, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–64. doi:10.2337/dc11-1909.
   PubMed Web of Science ®Google Scholar
• Bourne RR, Stevens GA, White RA, Smith JL, Flaxman SR, Price H, Jonas JB, Keeffe J, Leasher J, Naidoo K, et al. Causes of vision loss worldwide, 1990–2010: a systematic analysis. Lancet Glob Health. 2013;1(6):e339–49. doi:10.1016/S2214-109X(13)70113-X6.
   PubMed Web of Science ®Google Scholar
• Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124–36. doi:10.1016/S0140-6736(09)62124-3.
   PubMed Web of Science ®Google Scholar
• Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015 Sep 30;2:17. doi:10.1186/s40662-015-0026-2.
   PubMedGoogle Scholar
• Lee CS, Lee AY, Baughman D, Sim D, Akelere T, Brand C, Crabb DP, Denniston AK, Downey L, Fitt A, et al. The United Kingdom diabetic retinopathy electronic medical record users group: report 3: baseline retinopathy and clinical features predict progression of diabetic retinopathy. Am J Ophthalmol. 2017 Aug;180:64–71. doi:10.1016/j.ajo.2017.05.020.
   PubMed Web of Science ®Google Scholar
• Denniston AK, Chakravarthy U, Zhu H, Lee AY, Crabb DP, Tufail A, Bailey C, Akerele T, Al-Husainy S, Brand C, et al. The UK Diabetic Retinopathy Electronic Medical Record (UK DR EMR) users group, report 2: real-world data for the impact of cataract surgery on diabetic macular oedema. Br J Ophthalmol. 2017 Dec;101(12):1673–78. doi:10.1136/bjophthalmol-2016-309838.
   PubMed Web of Science ®Google Scholar
• Egan C, Zhu H, Lee A, Sim D, Mitry D, Bailey C, Johnston R, Chakravarthy U, Denniston A, Tufail A, et al. The United Kingdom diabetic retinopathy electronic medical record users group, report 1: baseline characteristics and visual acuity outcomes in eyes treated with intravitreal injections of ranibizumab for diabetic macular oedema. Br J Ophthalmol. 2017 Jan;101(1):75–80. doi:10.1136/bjophthalmol-2016-309313.
   PubMed Web of Science ®Google Scholar
• Harb W, Harb G, Chamoun N, Kanbar A, Harb M, Chanbour W. Severity of diabetic retinopathy at the first ophthalmological examination in the Lebanese population. Ther Adv Ophthalmol. 2018 Aug 14;10:2515841418791950.
   Web of Science ®Google Scholar
• Almalki NR*, Almalki TM, Alswat K. Diabetics retinopathy knowledge and awareness assessment among the type 2 diabetics. Open Access Maced J Med Sci. 2018 Mar 15;6(3):574–77. doi:10.3889/oamjms.2018.221.
   PubMedGoogle Scholar
• Bruender MC, Benjamin N, Agostini HT, Stahl A, Ehlken C. Subjective evaluation of visual acuity is not reliable to detect disease activity in different exudative maculopathies. Graefes Arch Clin Exp Ophthalmol. 2018 Sep;256(9):1565–71. doi:10.1007/s00417-018-4021-x.
   PubMed Web of Science ®Google Scholar
• Holekamp NM. Overview of diabetic macular edema. Am J Manag Care. 2016 Jul;22(10 Suppl):s284–s291.
   PubMedGoogle Scholar
• Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Early treatment diabetic retinopathy study research group. Arch Ophthalmol. 1985;103(12):1796–806.
   PubMedGoogle Scholar
• Laursen ML, Moeller F, Sander B, Sjoelie AK. Subthreshold micropulse diode laser treatment in diabetic macular edema. Br J Ophthalmol. 2004;88:1173–79.
   PubMed Web of Science ®Google Scholar
• Do DV, Nguyen QD, Boyer D, Schmidt-Erfurth U, Brown DM, Vitti R, Berliner AJ, Gao B, Zeitz O, Ruckert R, et al. One-year outcomes of the da vinci study of VEGF trap-eye in eyes with diabetic macular edema. Ophthalmology. 2012;119(8):1658–65. doi:10.1016/j.ophtha.2012.02.010.
   PubMed Web of Science ®Google Scholar
• Fong DS, Luong TQ, Contreras R, Jimenez JJ, Custis PH, Patel V, Campbell JH. Treatment patterns and 2-year vision outcomes with bevacizumab in diabetic macular edema: an analysis from a large U.S. Integrated health care system. Retina. 2018;38(9):1830–38. doi:10.1097/IAE.0000000000001790.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789–801. doi:10.1016/j.ophtha.2011.12.039.
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Ferris FL, Hampton GR, Jhaveri C, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123(6):1351–59. doi:10.1016/j.ophtha.2016.02.022.
   PubMed Web of Science ®Google Scholar
• Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, Baumal C. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109(5):920–27. doi:10.1016/S0161-6420(02)00975-2.
   PubMed Web of Science ®Google Scholar
• Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li X-Y, Cui H, Hashad Y, Whitcup SM. Ozurdex MEAD study group three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904–14. doi:10.1016/j.ophtha.2014.04.024.
   PubMed Web of Science ®Google Scholar
• Veritti D, Sarao V, Diplotti L, Samassa F, Lanzetta P. Fluocinolone acetonide for the treatment of diabetic macular edema. Expert Opin Pharmacother. 2017 Oct;18(14):1507–16. doi:10.1080/14656566.2017.1363182.
   PubMed Web of Science ®Google Scholar
• VanderBeek BL, Shah N, Parikh PC, Ma L. Trends in the care of diabetic macular edema: analysis of a national cohort. PLoS One. 2016;11(2):e0149450. doi:10.1371/journal.pone.0149450.
   PubMed Web of Science ®Google Scholar
• Kiss S, Liu Y, Brown J, Holekamp NM, Almony A, Campbell J., Kowalski JW. Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema. Clin Ophthalmol. 2014;8:1611–21. doi:10.2147/OPTH.S60893.
   PubMedGoogle Scholar
• Dugel PU, Layton A, Varma RB. Diabetic macular edema diagnosis and treatment in the real world: an analysis of medicare claims data (2008 to 2010). Ophthalmic Surg Lasers Imaging Retina. 2016;47(3):258–67. doi:10.3928/23258160-20160229-09.
   PubMed Web of Science ®Google Scholar
• Weiss M, Sim DA, Herold T, Schumann RG, Liegl R, Kern C, Kreutzer T, Schiefelbein J, Rottmann M, Priglinger S, et al. Compliance and adherence of patients with diabetic macular edema to intravitreal anti-vascular endothelial growth factor therapy in daily practice. Retina. 2017 Oct 24. 1. [Epub ahead of print]. doi:10.1097/IAE.0000000000001892.
   Web of Science ®Google Scholar
• Jansen ME, Krambeer CJ, Kermany DS, Waters JN, Tie W, Bahadorani S, Singer J, Comstock JM, Wannamaker KW, Singer MA, et al. Compliance study group. Appointment compliance in patients with diabetic macular edema and exudative macular degeneration. Ophthalmic Surg Lasers Imaging Retina. 2018;49(3):186–90. doi:10.3928/23258160-20180221-06.
   PubMed Web of Science ®Google Scholar
• Best AL, Fajnkuchen F, Nghiem-Buffet S, Grenet T, Quentel G, Delahaye-Mazza C, Cohen SY, Giocanti-Aurégan A. Treatment efficacy and compliance in patients with diabetic macular edema treated with ranibizumab in a real-life setting. J Ophthalmol. 2018 Apr 18;2018:4610129. doi:10.1155/2018/4610129.
   PubMed Web of Science ®Google Scholar
• Obeid A, Gao X, Ali FS, Talcott KE, Aderman CM, Hyman L, Ho AC, Hsu J. Loss to follow-up in patients with proliferative diabetic retinopathy after panretinal photocoagulation or intravitreal anti-VEGF injections. Ophthalmology. 2018;125(9):1386–92. doi:10.1016/j.ophtha.2018.02.034.
   PubMed Web of Science ®Google Scholar
• Grosser LR. Health belief model aids understanding of patient behavior. Aorn J. 1982;35:1056–59.
   PubMedGoogle Scholar
• Janz NK, Becker MH. The health belief model: a decade later. Health Educ Q. 1984;11(1):1–47. doi:10.1177/109019818401100101.
   PubMedGoogle Scholar
• Strecher VJ, Rosenstock IM. The health belief model. Cambridge Handb Psychol, Health Med. 1997;113–17.
   Google Scholar
• Conner M, Norman P. Predicting health behaviour. Glasgow: Bell & Bain Ltd; 2005.
   Google Scholar
• World Medical A. World medical association declaration of helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–94. doi:10.1001/jama.2013.281053.
   PubMed Web of Science ®Google Scholar
• Droege KM, Muether PS, Hermann MM, Caramoy A, Viebahn U, Kirchhof B, Fauser S. Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life. Graefe’s Arch Clin Exp Ophthalmol. 2013;251(5):1281–84. doi:10.1007/s00417-012-2177-3.
   PubMed Web of Science ®Google Scholar
• Boulanger-Scemama E, Querques G, About F, Puche N, Srour M, Mane V, Massamba N, Canoui-Poitrine SEH. Ranibizumab for exudative age-related macular degeneration: a five year study of adherence to follow-up in a real-life setting. J Fr Ophtalmol. 2015;38(7):620–27. doi:10.1016/j.jfo.2014.11.015.
   PubMed Web of Science ®Google Scholar
• Boyle J, Vukicevic M, Koklanis K, Itsiopoulos C. Experiences of patients undergoing anti-VEGF treatment for neovascular age-related macular degeneration: a systematic review. Psychol Health Med. 2015;20(3):296–310. doi:10.1080/13548506.2014.936886.
   PubMed Web of Science ®Google Scholar
• Senra H, Ali Z, Balaskas K, Aslam T. Psychological impact of anti-VEGF treatments for wet macular degeneration-a review. Graefe’s arch clin exp ophthalmol = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2016;254(10):1873–80. doi:10.1007/s00417-016-3384-0.
   PubMed Web of Science ®Google Scholar
• Bowers KA. Explaining health behavior: the health belief model. Nurs Adm Q. 1980;4:41–46.
   PubMedGoogle Scholar
• Abu Hussein NB, Eissa EM, Abdel-Kader AA. Analysis of factors affecting patients’ compliance to topical antiglaucoma medications in Egypt as a developing country model. J Ophthalmol. 2015;2015:234157, 7 p. doi:10.1155/2015/234157.
   Web of Science ®Google Scholar
• Ross EL, Hutton DW, Stein JD, Bressler NM, Jampol LM, Glassman AR. Diabetic retinopathy clinical research network. Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment: analysis from the diabetic retinopathy clinical research network comparative effectiveness trial. JAMA Ophthalmol. 2016;134(8):888–96. doi:10.1001/jamaophthalmol.2016.1669.
   PubMed Web of Science ®Google Scholar
• Brown GC, Brown MM, Turpcu A, Rajput Y. The cost-effectiveness of ranibizumab for the treatment of diabetic macular edema. Ophthalmology. 2015;122(7):1416–25. doi:10.1016/j.ophtha.2015.03.032.
   PubMed Web of Science ®Google Scholar
• Dewan V, Lambert D, Edler J, Kymes S, Apte RS. Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2012;119(8):1679–84. doi:10.1016/j.ophtha.2012.01.049.
   PubMed Web of Science ®Google Scholar
• Stein JD, Newman-Casey PA, Kim DD, Nwanyanwu KH, Johnson MW, Hutton DW. Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema. Ophthalmology. 2013;120(9):1835–42. doi:10.1016/j.ophtha.2013.02.002.
   PubMed Web of Science ®Google Scholar